<DOC>
	<DOCNO>NCT01979952</DOCNO>
	<brief_summary>This 6 month multi-centre , prospective , randomize , placebo control , double blind clinical trial follow conversion arm active nintedanib additional 6 month compare effect nintedanib 150mg BID progression IPF measure use HRCT , lung function , 6MWT , biomarkers , PROs continue treatment assessment 18 month .</brief_summary>
	<brief_title>Nintedanib Twice Daily v Placebo Patients Diagnosed With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Written Informed Consent consistent International Conference Harmonisation Good Clinical Practice ( ICHGCP ) local law sign prior entry study 2 . Patient age &gt; = 40 year Visit 1 . 3 . IPF diagnose , accord 2011 ATS/ERS/JRS/ALAT IPF guideline diagnosis management , within 5 year reaffirm apply 2011 Guidelines ( P1107084 ) diagnose &gt; 2 year 5 year Visit 1 , . Diagnosis must confirm chest HRCT take within 24 month Visit 1 . All HRCT result report possible inconsistent usual interstitial pneumonia ( UIP ) must confirmatory pathology . 4 . DLCO ( correct Hb ) : 30 % 79 % predict normal 5 . FVC &gt; = 50 % predict normal Visit 1 Visit 2 Exclusion criterion : 1 . AST , ALT &gt; 1.5 fold ULN 2 . Bilirubin &gt; 1.5 fold ULN 3 . Bleeding risk : 1 . Patients require fibrinolysis , fulldose therapeutic anticoagulation ( e.g . vitamin K antagonist , dabigatran , heparin , hirudin ) , high dose antiplatelet therapy . Exceptions : prophylactic low dose heparin heparin flush need maintenance indwell intravenous device ( e.g . enoxaparin 4000 IU s.c. per day ) prophylactic use antiplatelet therapy ( e.g . acetyl salicylic acid 325 mg/d , clopidogrel 75 mg/d , equivalent dos antiplatelet therapy ) 2 . History hemorrhagic Central Nervous System ( CNS ) event within 12 month 3 . Any follow within 3 month : Haemoptysis haematuria . Active gastrointestinal bleeding ulcer . Major injury surgery . 4 . Coagulation parameter : International normalise ratio ( INR ) &gt; 2 , prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 150 % institutional ULN . 4 . Planned major surgery within next 3 month , include lung transplantation , major abdominal major intestinal surgery . 5 . Thrombotic risk 1 . Known inherited predisposition thrombosis . 2 . History thrombotic event ( include stroke transient ischemic attack ) within 12 month 6 . Current plan usage investigational drug course trial 7 . Previous treatment nintedanib within clinical trial previous 3 month discontinuation nintedanib study treatment due adverse event 8 . Known hypersensitivity trial drug component 9 . A disease condition opinion investigator may put patient risk participation trial limit patient 's ability participate trial . Patients exclude require great 12L/min oxygen , ambulatory require use walker cane 6 Minute Titration Walk Test . Patients complete 6 Minute Titration Walk Test exclude participation . 10 . Alcohol drug abuse opinion investigator would interfere trial participation . 11 . Pregnant woman woman breast feed child bear potential use two effective method birth control ( one barrier one highly effective nonbarrier ) least 1 month prior trial and/or commit use 3 month end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>